Creso Pharma Limited chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 0.01
Dividend & YieldN/A$ (N/A)
Beta 3.38
Market capitalization 52.84M
Operating cash flow -22.38M
ESG Scores unknown

Company description

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.38M 259.59k 16.96k -691.76k
Total Cashflows From Investing Activities -4.14M -3.34M -831.69k -1.37M
Net Borrowings 2.43M 1.3M 5.09M -200.62k
Total Cash From Financing Activities 6.23M 10.04M 13.65M 24.89M
Change To Operating Activities 27.42k 20.31k -1.48k 348.41k
Issuance Of Stock 1.36M 9.84M 12.47M 26.53M
Net Income -16.76M -15.05M -30.78M -30.03M
Change In Cash -6.03M -3.59M 3.25M 1.14M
Effect Of Exchange Rate 46.46k -124.67k 50.14k -6.59k
Total Cash From Operating Activities -8.17M -10.17M -9.62M -22.38M
Depreciation 38.72k 397.96k 345.11k 845.64k
Change To Account Receivables -9.79k -356.88k 1.06M 465.07k
Other Cashflows From Financing Activities 2.44M -1.09M -3.91M -1.43M
Change To Netincome 7.59M 6.11M 18.84M 6.39M
Capital Expenditures -6.73M -1.92M -44.36k -450.92k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 286.54k 286.03k
Income Before Tax -16.85M -15.34M -30.78M -30.03M
Net Income -16.76M -15.05M -30.78M -30.03M
Selling General Administrative 9.42M 8.79M 9.46M 26.86M
Gross Profit 204.82k 2.13M -3.87M -400.39k
Ebit -15.76M -9.95M -14.35M -28.35M
Operating Income -15.76M -9.95M -14.35M -28.35M
Interest Expense -76.45k -1.69M -3.22M -523.67k
Income Tax Expense
Total Revenue 558.38k 3.63M 2.46M 6.22M
Cost Of Revenue 353.57k 1.5M 6.33M 6.62M
Total Other Income ExpenseNet -1.08M -5.39M -16.43M -1.68M
Net Income From Continuing Ops -16.85M -15.34M -30.78M -30.03M
Net Income Applicable To Common Shares -16.76M -15.05M -30.78M -30.03M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 5.78M 5.76M 5.47M 1.56M
Total Stockholder Equity 16.59M 17.27M 13.65M 27.76M
Other Current Liabilities 452.24k 179.58k 393.69k 117.26k
Total Assets 22.28M 22.66M 19.12M 29.31M
Common Stock 38.22M 46.53M 71.79M 109.95M
Other Current Assets 623.1k 855.12k 338.79k 686.5k
Retained Earnings -36.43M -51.86M -82M -94.82M
Treasury Stock 14.8M 22.6M 23.86M 12.63M
Cash 6.39M 2.8M 6.05M 7.18M
Total Current Liabilities 5.78M 5.39M 5.47M 1.56M
Other Stockholder Equity 14.8M 22.6M 23.86M 12.63M
Property, Plant, and Equipment 9.9M 11.27M 9.91M 10.44M
Total Current Assets 8.28M 6.92M 7.94M 10.14M
Net Tangible Assets 12.49M 12.8M 12.38M 19.44M
Net Receivables 823.52k 1.27M 441.12k 872.32k
Accounts Payable 455.88k 1.03M 633.92k 281.59k


Insider Transactions

Here are the insider transactions of stock shares related to Creso Pharma Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Grundy (Christopher)D2021-12-31Chief Financial Officer300k
Ellingford (James)D2021-07-14Director (Executive)500k
Wachtel (Boaz)D2021-07-14Director (Non-Executive)500k
Blumenthal (Adam)Sale at price 0.11 per share.D2021-07-07Director (Non-Executive)7.08M
Blumenthal (Adam)Sale at price 0.10 per share.D2021-07-07Director (Non-Executive)25.75M
Wernli (Miriam Halperin)D2021-03-16Former300k
Ellingford (James)D2021-03-09Director (Executive)797.5k
Grundy (Christopher)D2020-12-31Chief Financial Officer600k
Blumenthal (Adam)Other at price 0.02 per share.D2020-12-23Director (Non-Executive)137.46M
Blumenthal (Adam)Other at price 0.04 per share.D2020-10-12Director (Non-Executive)833.33k
Wernli (Miriam Halperin)Other at price 0.04 per share.D2020-10-12Chief Executive Officer833.33k
Blumenthal (Adam)D2020-02-12Director (Non-Executive)1.96M
Grundy (Christopher)D2019-12-31Chief Financial Officer26k
Ellingford (James)D2019-07-31Director (Non-Executive)100k
Blumenthal (Adam)D2019-07-02Director (Non-Executive)750k
Ellingford (James)D2019-07-02Director (Non-Executive)250k
Wachtel (Boaz)D2019-07-02Chairman of the Board1.5M
Wernli (Miriam Halperin)D2019-07-02Chief Executive Officer4.4M
Grundy (Christopher)D2018-12-31Divisional Officer4.91k
Wernli (Miriam Halperin)D2018-12-31Chief Executive Officer150k
Ellingford (James)D2018-07-27Director (Non-Executive)100k
Blumenthal (Adam)D2018-07-23Director (Non-Executive)1.5M
Buckingham (Simon Hugh William)D2017-12-31Former200k
Blumenthal (Adam)D2017-03-31Director (Non-Executive)2.25M
Buckingham (Simon Hugh William)D2017-03-31Director (Non-Executive)200k
Ellingford (James)D2017-03-31Director (Non-Executive)750k
Wachtel (Boaz)D2017-03-31Chairman of the Board4.5M
Wernli (Miriam Halperin)D2017-03-31Chief Executive Officer5.25M

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Creso Pharma Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Creso Pharma Limited

Here is the result of two systematic investment strategies applied to Creso Pharma Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Creso Pharma Limited

The following chart shows the equity curve of the two systematic investment strategies applied to Creso Pharma Limited:

Creso Pharma Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 82.26% on the backtest period.

Performance at glance

Performance

82.26 %

Latent gain

1851.01 $

Invested capital

2250.07 $

Annualized return

19.49 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Creso Pharma Limited

This is the result of two momentum investment strategies applied to Creso Pharma Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Creso Pharma Limited

The following chart shows all the entries opened by the momentum investment system on Creso Pharma Limited:

Creso Pharma Limited momentum entries
  • The first momentum investment strategy would give 57.3% of return on Creso Pharma Limited. That represents 2435.39$ of latent gain with 4250.48$ of employed capital.
  • The second momentum investment strategy would give 121.37% of return on Creso Pharma Limited. That represents 4550.68$ of latent gain with 3749.57$ of employed capital.
Performance at glance (1Q Momentum)

Performance

57.3 %

Latent gain

2435.39 $

Invested capital

4250.48 $

Annualized return

166.1 %
Performance at glance (2Q Momentum)

Performance

121.37 %

Latent gain

4550.68 $

Invested capital

3749.57 $

Annualized return

32.45 %

Momentum equity curve on Creso Pharma Limited

The following chart shows the equity curve of the two momentum strategies applied to Creso Pharma Limited:

Creso Pharma Limited momentum equity

Note: the dividends potentially given by Creso Pharma Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Creso Pharma Limited

The following chart shows the employed capital evolution of the two momentum strategies on Creso Pharma Limited since the beginning:

Creso Pharma Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Creso Pharma Limited

Buy the dip entry openings on Creso Pharma Limited

Creso Pharma Limited

The performance achieved by the robo-advisor on Creso Pharma Limited is 368.75%. That represents 921.82$ of latent gain with 249.98$ of employed capital. The following chart shows Creso Pharma Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Creso Pharma Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

368.75 %

Latent gain

921.82 $

Invested capital

249.98 $

Annualized return

166.1 %

Equity curve of the strategy applied to Creso Pharma Limited

The following chart shows the result of the investment strategy applied to Creso Pharma Limited:

Creso Pharma Limited

Note: the dividends potentially given by Creso Pharma Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Creso Pharma Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on Creso Pharma Limited:

Creso Pharma Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Creso Pharma Limited

In this section, I will compare the three previous investment strategies applied to Creso Pharma Limited.

Equity curve comparison on Creso Pharma Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Creso Pharma Limited investment strategy comparison

Employed capital comparison on Creso Pharma Limited

Creso Pharma Limited investment comparison

Performance comparison on Creso Pharma Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 82.26% 1851.01$ 2250.07$ 19.49%
Momentum 1 quarter 57.3% 2435.39$ 4250.48$ 14.4%
Momentum 2 quarters 121.37% 4550.68$ 3749.57$ 32.45%
Non-directional 368.75% 921.82$ 249.98$ 166.1%
Annualized return comparison

Automatic investment

19.49 %

Momentum 1Q

32.45 %

Momentum 2Q

32.45 %

Non-directional

166.1 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Creso Pharma Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Creso Pharma Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of Creso Pharma Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Creso Pharma Limited
Country Australia
City Nedlands
Address 145 Stirling Highway
Phone 61 8 9389 3180
Website www.cresopharma.com
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XASX
Ticker CPH.XASX
Market www2.asx.com.au

Creso Pharma Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown